On Wednesday, the FDA approved an investigational device exemption (IDE) for Exact Sciences’ multi-cancer early detection (MCED) test, clearing the way for the test’s use in clinical studies. It’s a key milestone in our development of a rigorous and comprehensive MCED program. We look forward to the next phase, the launch of real-world evidence studies, in the coming months. The achievement wouldn’t be possible without the dedication, grit, and innovative spirit of the Exact Sciences team. Thank you for all you do.
Exact Sciences
Biotechnology Research
Madison, Wisconsin 104,966 followers
Changing the way we think about detecting and treating cancer.
About us
At Exact Sciences, our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. We're hiring! Our organization offers something for everyone, at all stages of careers and from all backgrounds. Let's take on cancer, together.
- Website
-
http://exactsciences.com
External link for Exact Sciences
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Madison, Wisconsin
- Type
- Public Company
- Specialties
- Colon cancer screening, Screening test research and development, Non-invasive cancer screening, Precision oncology, and Genomic testing
Locations
Employees at Exact Sciences
Updates
-
We were proud to partner with the NAHJ (National Association of Hispanic Journalists) to lead an impactful discussion around disparities in cancer outcomes for Latinos and how journalists can help educate and advocate for the community. Thank you to Veronica Descotte and our expert panelists, Regina Barragan, Marielle McLeod, MHA, CPN, and Marcela Mazo Canola for sharing your expertise. #NAHJ2024.
-
We’re thrilled to share that Cologuard® is now covered for Medicaid patients in Washington. By providing access to a high-sensitivity colorectal cancer screening option that can be done at home, this coverage enables patients in Washington to catch this disease earlier, when it’s more treatable.* *Based on 5-year survival
-
Computer simulations are a valuable tool in cancer research, used to help predict health outcomes and guide public health priorities. Discover how these simulations use mathematical equations and real-world data to calculate how different scenarios may affect people: https://bit.ly/4ccYmE5
-
We are honored to be named a 2024 Top Workplace by Arizona Top Workplaces. This award is centered on employee feedback and highlights our commitment to ensuring team members feel respected, supported, and empowered. Thank you to our entire team for fostering an outstanding work environment while fulfilling our purpose of helping eradicate cancer. https://bit.ly/3W4HE4f #WeAreExact
-
Creating a safe and welcoming environment for employees is central to everything we do. We celebrated Pride month with enthusiasm and commitment to inclusivity. Here's a look at how our teammates participated at Exact Sciences and in the community: • Recorded 53,000 minutes of movement for a Move with Pride initiative, to support The Trevor Project • Launched an internal Pride Inclusion Network as an avenue for meaningful dialogue and intentional activities, that is already 320 members strong • Volunteered at Milwaukee Pride Fest, the largest LGBTQ+ festival in Wisconsin • Sorted food at Second Harvest of Silicon Valley • Volunteered with Valley of the Sun United Way in Phoenix Read about our Move with Pride initiative and how reaching our team’s goals helped an LGBTQ+ nonprofit organization: https://bit.ly/3xCREIq #TeamExactSciences #WeAreExact #PrideMonth
-
We're proud to stand with the American Cancer Society Cancer Action Network (ACS CAN) and 520+ organizations in support of the #MCEDAct to ensure timely access to multi-cancer early detection screening tests for Medicare enrollees to help close gaps that exist in today’s cancer screening.
Tomorrow, the U.S. House Committee on Ways and Means will mark-up the bipartisan Nancy Gardner Sewell Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act, which would ensure that Medicare enrollees have access to #MCED tests once approved by the FDA and clinical benefit is shown. “In 2024, more than 2 million Americans are expected to be diagnosed with cancer, and over 1 million of those cases are expected to be diagnosed in individuals over the age of 65...We urge Congress to pass the #MCEDAct to ensure access to early detection for our most vulnerable communities and save lives.” -Dr. Karen Knudsen MBA PhD, CEO of the American Cancer Society and ACS CAN Read the full statement:
ACS CAN Applauds House’s Commitment to Bipartisan Legislation Critical to Advancing Innovative Cancer Early Detection Tests
fightcancer.org
-
The AmFam Championship is more than just a showcase of top-tier talent. It’s an opportunity to make an impact in our community. We were honored to give a grant to Make-A-Wish Wisconsin, an organization committed to supporting children with critical illnesses. For some, the AmFam Championship is also an opportunity to play a round of golf with a professional. When Make-A-Wish recipient, Noah, took the course in this year’s pro-am event, it served as a powerful reminder of the impact we can make in supporting patients. Read more about his story here: https://bit.ly/45HqBZ1
Teeing up a good cause
exactsciences.com
-
With over 300 colorectal cancer patients, survivors, and loved ones in attendance at the 2024 Cologuard Classic by Exact Sciences, the tournament has truly grown into a celebration for the colorectal cancer community. This #NationalCancerSurvivorsMonth, hear from a few colorectal cancer patients as they share what it’s meant to be able to attend the tournament: https://bit.ly/4baQcLl #CologuardClassic
-
Trivia time! What chemical element did Marie & Pierre Curie discover at the beginning of the 20th century? Here’s a hint: this breakthrough led to the development of a treatment that is widely used today to help treat cancer. Find the answer and learn more about this form of breast cancer treatment from our very own Jennifer Racz: https://lnkd.in/gHkWeiBY Katie Couric Media
This content isn’t available here
Access this content and more in the LinkedIn app
Affiliated pages
Similar pages
Browse jobs
Stock
EXAS
NASDAQ
20 minutes delay
$49.67
2.62 (5.569%)
- Open
- 47.43
- Low
- 46.84
- High
- 49.88
Data from Refinitiv
See more info on